CIMAB SA de CV

Torreón, Coahuila 27000

1 studies enrolling now · 9 studies all time

What they study most

Breast Cancer, HER2-Positive Primary Breast Cancer, Heart Failure, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity, Overweight, Primary Sjogrens Disease, Residual Invasive Breast Cancer, Systemic Lupus Erythematosus

Studies at this site

• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome — Running, not enrolling
• A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial — Completed
• A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus — Stopped early
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed
• A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) — Completed
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus — Stopped early